imidapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 1424 89371-37-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imidapril hydrochloride
  • tanatril
  • imidapril
  • TA-6366
  • imidapril HCl
  • Molecular weight: 405.45
  • Formula: C20H27N3O6
  • CLOGP: 1.53
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 116.25
  • ALOGS: -2.96
  • ROTB: 10

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 54 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1 28
kinase-selectivity-class AXL,BRAF,EPHB4,GRK2,MAP2K6,MAPK7,STK33,TEK,TGFBR1 9
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.723 Moderate 0.69
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.008 % Moderate 0.69

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1993 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 53.69 42.58 22 592 109474 90518359
Renal impairment 44.33 42.58 19 595 105402 90522431

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 54.35 28.50 22 955 31147 42589211
Interstitial lung disease 32.60 28.50 21 956 78441 42541917
Cardiac failure 31.18 28.50 23 954 106833 42513525

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 80.71 29.09 45 1709 187581 110399964
Cerebral infarction 75.38 29.09 29 1725 51809 110535736
Renal impairment 61.96 29.09 38 1716 188407 110399138
Hepatic function abnormal 54.20 29.09 27 1727 89268 110498277
Interstitial lung disease 50.68 29.09 30 1724 139304 110448241
Altered state of consciousness 45.85 29.09 21 1733 57605 110529940
Embolic stroke 32.95 29.09 10 1744 8733 110578812

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA16 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:49103 drug metabolite

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs
benazeprilcaptoprilcilazaprildelaprilenalaprilfosinoprillisinoprilmoexiprilperindoprilquinaprilramiprilspirapril show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.49 acidic
pKa2 4.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 5 CHEMBL SCIENTIFIC LITERATURE

External reference:

IDSource
D01549 KEGG_DRUG
89396-94-1 SECONDARY_CAS_RN
C0165703 UMLSCUI
CHEBI:135654 CHEBI
CHEMBL317094 ChEMBL_ID
DB11783 DRUGBANK_ID
C065166 MESH_SUPPLEMENTAL_RECORD_UI
5464343 PUBCHEM_CID
6377 IUPHAR_LIGAND_ID
6394 INN_ID
BW7H1TJS22 UNII
259335 RXNORM
007791 NDDF
007792 NDDF
395741003 SNOMEDCT_US
395984005 SNOMEDCT_US
426163004 SNOMEDCT_US
C0246977 UMLSCUI
CHEMBL99701 ChEMBL_ID
89371-44-8 SECONDARY_CAS_RN
5464344 PUBCHEM_CID
6378 IUPHAR_LIGAND_ID
7209 INN_ID
C078006 MESH_SUPPLEMENTAL_RECORD_UI
WUU07Y30IA UNII
CHEBI:141520 CHEBI
BW7H1TJS22 INXIGHT DRUGS
WUU07Y30IA INXIGHT DRUGS

Pharmaceutical products:

None